别名 COVID-19-Related Pediatric Inflammatory Multisystem Syndrome、MIS-C、MIS-C - multisystem inflammatory syndrome in children + [43] |
简介 A rare syndrome temporally associated with COVID-19 in children, marked by persistent fever, inflammation (neutrophilia, elevated C-reactive protein (CRP), and lymphopenia), poor function in one or more organs, and other specific clinical and laboratory features not attributable to other infections. The characteristics of this syndrome appear to be similar to toxic shock syndrome and Kawasaki disease. The following variable signs and symptoms have been most commonly reported to date: coagulopathy, cardiac dysfunction, diarrhea, abdominal distension, other GI symptoms (with some children having positive stool tests for SARS-CoV-2), and acute kidney injury. Respiratory symptoms are not always a prominent feature in these cases. |
作用机制 EGFR拮抗剂 [+1] |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-03-22 |
申办/合作机构- |
开始日期2023-12-01 |
申办/合作机构 |
开始日期2023-11-01 |
申办/合作机构- |